A detailed history of New Edge Advisors, LLC transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 100 shares of PCRX stock, worth $2,032. This represents 0.0% of its overall portfolio holdings.

Number of Shares
100
Previous 100 -0.0%
Holding current value
$2,032
Previous $2,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$27.7 - $35.48 $5,179 - $6,634
-187 Reduced 65.16%
100 $2,000
Q2 2023

Aug 14, 2023

BUY
$36.12 - $47.5 $6,754 - $8,882
187 Added 187.0%
287 $11,000
Q1 2023

May 12, 2023

SELL
$35.53 - $43.38 $142 - $173
-4 Reduced 3.85%
100 $4,000
Q4 2022

Feb 14, 2023

BUY
$38.19 - $57.45 $3,971 - $5,974
104 New
104 $4,000
Q3 2017

Nov 13, 2017

SELL
$35.7 - $39.5 $5,640 - $6,241
-158 Closed
0 $0
Q2 2017

Aug 16, 2017

BUY
N/A
158
158 $0

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $932M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.